A Phase I Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs DS 3032b (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.
- 15 Jul 2016 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
- 15 Jul 2016 Planned initiation date changed from 1 Jul 2016 to 1 Aug 2016.